The layout has been a long time GlaxoSmithKline is difficult to return to the Chinese market

After GlaxoSmithKline executives announced overseas that they would leave China in the face of sky-high fines, there was no end. Previously, market rumors, the Chinese government, or a 20 billion-dollar fine against GlaxoSmithKline in the bribery scandal, is the main reason why one of its executives is claiming to be out of China, and China's public relations agency, which is a huge shock to the industry from overseas, has responded lightly by saying: " GlaxoSmithKline has entered China since the beginning of the last century and has a long history in China. China is a very important market in its development strategy, our long-term commitment to China will not change, and always committed to the long-term development of the Chinese market. "The official reply looks somewhat ambiguous and represents a complex dilemma for GlaxoSmithKline at the moment," he said. However, in the eyes of the industry, GlaxoSmithKline has entered China in 26, completed the layout of the lines, the market share is substantial, so it is impossible to really withdraw from China, the exit is more like a face of a fine negotiation stance. According to the commercial layout data, GlaxoSmithKline first entered China for 1987 years. At that time GlaxoSmithKline's predecessor--shi-cheng group and Tianjin in the new drug industry and Tianjin Taiping Group joint venture to establish Sino-US Tianjin Shi Grams pharmaceutical company, is second only to Xi ' an Yang Sen of Chinese foreign pharmaceutical companies. Previously, GlaxoSmithKline had sold a Chinese factory. In August 2004, GlaxoSmithKline signed an agreement with Taiji group in Chongqing to sell its first joint venture company GlaxoSmithKline (Chongqing) Co., Ltd., which was established in China, with a price of 106 million yuan, and 130 acres of land. September 9 This year, the company announced the sale of its two soft drink brands to Japan Suntory Group, 2.1 billion U.S. dollars. However, these sales are not core assets, but GlaxoSmithKline's huge industrial chain of "marginal products" in the Chinese market, after years of operation, the company has a number of products occupy a leading position in the market share. "For pharmacies, the new Kang and fen will be essential drugs, but also pharmacies OTC drugs, one of the best selling products." "Beijing Happy person pharmacy a person in charge said. The person in charge, in the one or two-line city, new Tai grams sales of the first three of cold medicine, three or four-line city on the poor. According to the over-the-counter Drug association's ranking of the 2012 rankings, the new Kang, a cold cough anti-allergy drugs first, Fen must live in the first place antipyretic and analgesic drugs. Data show that China and the United States is currently the largest over-the-counter drug production companies, more than 2 billion yuan in sales, the new Kang grams is more than 1 billion yuan, Fen will also occupy more than 1/3. This is just an over-the-counter drug, and GlaxoSmithKline also plays an important role in the domestic pharmaceutical market in the prescription drug market. The dean of a second-tier hospital said that this was mainly GlaxoSmithKline drugs of many kinds, good quality. He introduced, such as hepatitis medication lamivudine, although the old medicine for many years, but patients need to take life. According to statistics, lamivudine in the domestic prescription drug market sales in 2006 that is more than 1 billion yuan. In addition, GlaxoSmithKline's antibiotic products are also in many hospitalsUse, respiratory drugs seretide overlap and Ventolin, is also the most common drug. According to data, GlaxoSmithKline last year sold more than 7 billion yuan in China. In the second quarter of this year, the company's drug and vaccine sales in China increased by 14% to 212 million pounds (2 billion yuan). "We are still focused on the Chinese market and will continue to provide medical products to meet the needs of Chinese patients, and we hope to maintain constructive long-term cooperation with the Chinese Government in the course of health reform," he said. GlaxoSmithKline's PR manager, 方芳, said she had not given a positive response to the fact that she had actually withdrawn from China. "We are now fully cooperating with the investigation by the Chinese government and are seeking to reach a satisfactory solution as soon as possible." 方芳 said, according to her, GlaxoSmithKline in the domestic investment has been more than 500 million U.S. dollars, in China has more than 7,000 employees, currently in China has a global full-featured research and Development center and six production base. Data show that since 2010, GlaxoSmithKline in China repeatedly has a big investment in fixed assets. In December 2010, GlaxoSmithKline bought Nanjing Mei Rui Pharmaceutical Co., Ltd. with 70 million dollars in cash. Nanjing Mei Rui Pharmaceutical Co., Ltd. is a pagoda pharmaceutical group in China's operating entity, its product line including urinary and allergy products portfolio. September 2011, GlaxoSmithKline spent 39 million U.S. dollars, from Shenzhen Hai Wang Yingtorong Biotechnology Co., Ltd., the acquisition of the two sides of the joint venture Shenzhen GlaxoSmithKline King Hai Wang Biological Products Co., Ltd., the remaining 51% of the stake, mainly engaged in vaccine research, development and production and management. Other fixed assets investment also includes, 1984 established the Sino-American Tianjin Shi Grams Pharmaceutical Co., Ltd., registered capital of 29.94 million yuan; the establishment of GlaxoSmithKline in 1995 (Tianjin) Co., Ltd., registered capital of 71 million yuan; GlaxoSmithKline Pharmaceutical (Suzhou) Co., Ltd. was established by GlaxoSmithKline Group wholly-owned, GSK is currently the largest investment in China, the project is said to invest 135 million U.S. dollars. In addition, GlaxoSmithKline also set up Shanghai GlaxoSmithKline Biological Products Co., Ltd. in Shanghai, the same production of vaccines. An industry personage said, this year domestic medicine market scale will break through the trillion yuan mark, this to the transnational Medicine enterprise, is the rare opportunity, therefore GlaxoSmithKline will not easily give up. "When the world is short, you give up, the market will naturally be occupied by other competitors, so from this point of view, this exit statement has no leverage." ”